Pamneit Bhogal, MD
Family Medicine · Philadelphia, PANPI 1609045251
Payments from drug & device makers
Across 123 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$355
- GSK$238
- Boehringer Ingelheim$237
- Exact Sciences$210
- Pfizer$137
- Amgen$126
- plus $876 from 20 others
What the payments were for
- Food & beverage$2,179100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $355 |
| GSK | 9 | $238 |
| Boehringer Ingelheim | 13 | $237 |
| Exact Sciences | 7 | $210 |
| Pfizer | 7 | $137 |
| Amgen | 6 | $126 |
| Merck | 7 | $111 |
| Kowa Pharmaceuticals America, Inc. | 8 | $103 |
| Astellas Pharma US Inc | 5 | $99 |
| AbbVie(2 entities) | 4 | $50 |
| Sunovion Pharmaceuticals Inc. | 5 | $49 |
| Daiichi Sankyo Inc. | 2 | $49 |
| AstraZeneca | 4 | $48 |
| Inspire Medical Systems, Inc. | 2 | $44 |
| Johnson & Johnson | 1 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $41 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $40 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Radius Health, Inc. | 2 | $30 |
| Lilly USA, LLC | 2 | $27 |
| Hologic Sales And Service, LLC | 1 | $27 |
| Boston Scientific | 1 | $23 |
| Eisai Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Phadia US Inc. | 1 | $12 |
How this compares
$2,179 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 98 | $105,511 |
| EliquisApixaban | 80 | $83,278 |
| JanuviaSitagliptin Phosphate | 42 | $47,368 |
| TrulicityDulaglutide | 35 | $33,798 |
| JardianceEmpagliflozin | 24 | $29,265 |
| FarxigaDapagliflozin Propanediol | 17 | $27,665 |
| MounjaroTirzepatide | 11 | $26,592 |
| JanumetSitagliptin Phos/Metformin Hcl | 24 | $25,886 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $17,610 |
| RestasisCyclosporine | 28 | $16,579 |
| Breo ElliptaFluticasone/Vilanterol | 41 | $15,969 |
| VascepaIcosapent Ethyl | 22 | $14,279 |
| LinzessLinaclotide | 19 | $14,179 |
| MyrbetriqMirabegron | 16 | $11,917 |
| Mesalamine | 21 | $7,442 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $355 | $105,51198 claims |
| PfizerEliquis | $137 | $83,27880 claims |
| MerckJanuvia, Janumet | $111 | $73,25466 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $27 | $60,39046 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $238 | $33,58069 claims |
| AbbVieRestasis, Linzess, Synthroid | $50 | $33,33488 claims |
| Boehringer IngelheimJardiance | $237 | $29,26524 claims |
| AstraZenecaFarxiga | $48 | $27,66517 claims |
| Astellas Pharma US IncMyrbetriq | $99 | $11,91716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Philadelphia
- Daniel LinPhiladelphia$392K
- Glenn RosenPhiladelphia$367K
- Christopher ChambersPhiladelphia$350K
- Deborah WittPhiladelphia$226K
- Michael AttanasioPhiladelphia$214K
- Jonah MinkPhiladelphia$145K
- Celia EzidiegwuPhiladelphia$118K
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.